Clinical trial results, historical drug revenue, valuation models and more – delivered in 24 hours
$100 per drug analyzed. See exact pricing before you buy.
Get up to speed on drug markets with the click of a button.
Reports include disease descriptions, epidemiology data, clinical trial results for major pivotal studies, historical quarterly revenue for approved drugs, drug pricing, market sizing for each drug, and rNPV valuation models for approved drugs.
Reports currently cover approved drugs only. We will be adding pipeline coverage shortly. Reports are generated with AI, leveraging high quality data sources like the FDA Orange Book, drug labels, peer-reviewed articles, company filings, and more.
To learn more, click to view a full sample.
A genetic neuromuscular disorder characterized by progressive muscle weakness and atrophy due to degeneration of motor neurons in the spinal cord.
Drug Name | Mechanism | Company |
AI Value ($M)
|
Download rNPV model |
---|---|---|---|---|
FDA Approved Drugs
3 drugs
|
||||
Zolgensma
|
Gene therapy | Novartis |
$2377
|
|
Evrysdi
|
Small molecule: Survival of Motor Neuron 2 Splicing Modifier | Roche |
$7368
|
|
Spinraza
|
Oligonucleotide therapies: Survival Motor Neuron-2-directed RNA Interaction | Biogen |
$5531
|
Search for your disease area of interest in our comprehensive database of therapeutic indications.
See transparent pricing based on the number of drugs in your report. Each drug costs $100.
Securely check out with a credit card. No subscription required.
Your custom report will be delivered to your inbox in less than 24 hours, complete with Excel exports.
If we miss a key drug or critical datapoint, we'll revise the report free within 7 days